A PYMNTS Company

US: Mallinckrodt must face investors’ antitrust suit

By  |  August 1, 2019

Mallinckrodt must face a proposed class action lawsuit alleging it failed to disclose an imminent US$100 million Federal Trade Commission settlement resolving claims it illegally maintained a monopoly over an expensive drug, a federal judge has ruled.

    Get the Full Story

    Complete the form to unlock this article and enjoy unlimited free access to all PYMNTS content — no additional logins required.

    yesSubscribe to our daily newsletter, PYMNTS Today.

    By completing this form, you agree to receive marketing communications from PYMNTS and to the sharing of your information with our sponsor, if applicable, in accordance with our Privacy Policy and Terms and Conditions.

    US District Judge Dabney Friedrich in Washington, DC, on Tuesday, July 30, also held the plaintiffs sufficiently alleged the drugmaker and top executives misled investors about H.P. Acthar Gel’s reimbursement by Medicare and Medicaid and 2017 sales prospects.

    Full Content: Reuters

    Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.